Johnson & Johnson Announces Investments of About $55 Million in U.S.
Johnson & Johnson has announced investments of over $55 million in the U.S. across manufacturing, research and development, and technology.
This represents a “25% increase in investment compared to the previous four years and builds upon the Company’s already elevated U.S. investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act.” The investment begins with the ground-breaking of a new facility in Wilson, North Carolina.
Additionally, the investment will be put toward “three new advanced manufacturing facilities and the expansion of several existing sites across the Company’s Innovative Medicine and MedTech businesses that will create high-paying, high-technology jobs.” There will be “significant investments in extensive R&D infrastructure” aimed at developing treatments in areas like “oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.” The investment will also include “increased technology investments to help make drug discovery and development faster.”
The North Carolina facility will expand the company’s manufacturing capabilities for “cancer and immune-mediated and neurological diseases.” It will support “approximately 5,000 jobs during construction and create over 500 positions in North Carolina,” creating a $3 billion impact across the state in its first ten years of operation.
About the Author
Matt MacKenzieMatt MacKenzie
Associate Editor
Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care.
Related
ACUVUE
dreamstime_xxl_224177428